In a report released today, Julian Mitchell from Barclays maintained a Buy rating on Ingersoll Rand (IR – Research Report), with a price target of $105.00. The company’s shares closed yesterday at $93.62.
Mitchell covers the Industrials sector, focusing on stocks such as 3M, Ingersoll Rand, and Carrier Global. According to TipRanks, Mitchell has an average return of 16.5% and a 66.87% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ingersoll Rand with a $99.50 average price target, representing a 6.28% upside. In a report released on March 26, Stifel Nicolaus also maintained a Buy rating on the stock with a $102.00 price target.
IR market cap is currently $37.77B and has a P/E ratio of 49.17.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IR in relation to earlier this year. Most recently, in February 2024, Michael J Scheske, the VP & CAO of IR sold 11,401.00 shares for a total of $999,362.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ingersoll Rand (IR) Company Description:
Ingersoll Rand Inc. is a provider of mission-critical flow control and compression equipment and associated aftermarket parts,
consumables, and services. It manufactures compressor, pump, vacuum and blower products in its markets. Its segments are Industrials, Energy,
and Medical. In the Industrials segment, the company designs, manufactures, markets and services a broad range of air compression, vacuum and blower products
across a wide array of technologies and applications. In the Medical segment, it designs, manufactures and markets specialized gas, liquid and precision syringe pumps,
and compressors for use in the medical, laboratory and biotechnology end markets.
Read More on IR:
- Ingersoll-Rand’s Dover deal not a threat to bioprocessing space, says KeyBanc
- Ingersoll Rand to Acquire ILC Dover, Boosts Market Position
- Ingersoll-Rand to acquire ILC Dover for $2.33B, sees accretion
- Ingersoll-Rand initiated with a Neutral at Exane BNP Paribas
- Ingersoll-Rand price target raised to $101 from $85 at Barclays
